What is CorMedix's EBITDA?

CorMedix (CRMD) reported EBITDA of $74.2M in Q1 2026.

How has CorMedix's EBITDA changed year-over-year?

CorMedix's EBITDA increased by 265.8% year-over-year, from $20.29M to $74.2M.

What is the long-term trend for CorMedix's EBITDA?

Over 3 years (2021 to 2025), CorMedix's EBITDA has grown at a 77.6% compound annual growth rate (CAGR), from -$29.38M to $164.66M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

CorMedix CRMD EBITDA

Discontinued — last reported Q1 '26

EBITDA at other companies

Merit Medical SystemsMMSI

$74.65M+6.2%

ITG

Integer HoldingsITGR

$66.88M-15.8%

IAR

Integra LifeSciencesIART

$53.68M+111%

Emergent BiosolutionsEBS

$34M-54.8%

PfizerPFE

——

Merck & Co.MRK

——

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Calculated from CorMedix’s reported figures.

$63.7Mebit+

$10.5MDepreciation Depletion & Amortization

=$74.2M

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's EBITDA?: CorMedix (CRMD) reported EBITDA of $74.2M in Q1 2026.
How has CorMedix's EBITDA changed year-over-year?: CorMedix's EBITDA increased by 265.8% year-over-year, from $20.29M to $74.2M.
What is the long-term trend for CorMedix's EBITDA?: Over 3 years (2021 to 2025), CorMedix's EBITDA has grown at a 77.6% compound annual growth rate (CAGR), from -$29.38M to $164.66M.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.